In question are safety concerns about the drug's higher risk for blood clots and strokes (compared to other birth control pills) as well as FDA citations for improper marketing and quality control procedures at one of its plants.
The Times writes: "But even if Bayer can adequately respond to the safety and other concerns, some industry analysts say that the avalanche of criticism could tarnish the Yaz line’s image."
On September 26, it was reported that Swiss health regulators were investigating Yaz's role in the death of a young woman.
Have you registered with us yet?
Register now to enjoy more articles and free email bulletinsRegister